FDA budget language may shift LDT oversight

# FDA budget language may shift LDT oversight The Food and Drug Administration’s proposed budget for fiscal year 2027 is not a law, and it does not by itself rewrite the rules for laboratory-developed tests. But budget documents are where agencies show Congress what they want to do next, what powers they want added, and which programs they expect to emphasize. In the case of lab-developed tests, that matters because the regulatory ground has already shifted twice in the past two years. (fda.gov) A laboratory-developed test is a diagnostic test that is designed, manufactured, and used within a single laboratory rather than sold broadly as a commercial test kit. These tests are common in molecular pathology, cancer genomics, newborn screening, and other areas where hospitals and specialty labs often build assays for local clinical needs. (fda.gov) (congress.gov) For years, the core legal argument was about whether the Food and Drug Administration could treat these in-house tests as medical devices under the Federal Food, Drug, and Cosmetic Act, or whether they were better understood as laboratory services regulated mainly under the Clinical Laboratory Improvement Amendments framework. That split matters because device regulation brings premarket review, quality system requirements, adverse event reporting, and other obligations that are very different from the laboratory standards enforced through the Clinical Laboratory Improvement Amendments program. (congress.gov) The Food and Drug Administration tried to settle that question in May 2024, when it issued a final rule amending its regulations to make explicit that in vitro diagnostic products are devices “including when the manufacturer of these products is a laboratory.” That rule would have phased out the agency’s longstanding enforcement discretion approach and moved many laboratory-developed tests into the ordinary medical-device framework. (fda.gov 1) (fda.gov 2) Then the courts stepped in. On March 31, 2025, the U.S. District Court for the Eastern District of Texas vacated the final rule, holding that the Food and Drug Administration lacked statutory authority to regulate laboratory-developed tests in the way the rule attempted. (congress.gov) The agency’s own website now reflects that reversal. It says the May 6, 2024 final rule was vacated on March 31, 2025, and that on September 19, 2025 the Food and Drug Administration issued a final rule reverting the regulation text to what it had been before the 2024 change. (fda.gov) That is the backdrop for the new fiscal year 2027 budget request. The budget’s top-line request is $7.2 billion, but the more important signal for laboratories is that the document pairs funding priorities with legislative proposals, which is often how the agency tells Congress where it wants clearer authority. (fda.gov) (natlawreview.com) The National Law Review article that flagged this issue argues that the budget is less important for its headline number than for what sits underneath it: “concrete funding and legislative asks.” That framing is important because after the 2025 court loss, the Food and Drug Administration cannot simply assume it can revive the same laboratory-developed test policy through ordinary rulemaking without a stronger statutory footing. (natlawreview.com) (congress.gov) In practical terms, a budget request can work like an advance notice to the market. If the Food and Drug Administration asks Congress for new authorities, or signals that it wants to tighten oversight in areas tied to diagnostics, hospital laboratories, academic medical centers, and independent molecular labs may delay expansion plans until they know whether future tests will face new review costs or compliance duties. This is an inference from how federal budget requests and enforcement planning usually interact, not a statement that the budget itself changed the law. (fda.gov) (natlawreview.com) That uncertainty hits molecular testing especially hard because these assays can be expensive to validate, staff, and maintain even before any extra federal review is added. A health system deciding whether to launch a new cytology-linked molecular panel has to weigh equipment costs, pathologist time, bioinformatics support, reimbursement risk, and the possibility that the regulatory pathway could become more burdensome before the menu reaches scale. (congress.gov) (natlawreview.com) Clinical utility and reimbursement become the deciding filters in that environment. If a proposed assay clearly changes patient management and has a plausible payment path, a laboratory may still move ahead; if the test sits in a gray zone on coverage or physician demand, even a hint of future federal oversight can be enough to postpone investment. That is why budget language, even without immediate legal effect, can shape behavior inside laboratories and hospital finance offices. This is again an inference drawn from the policy context described in the budget discussion and the recent litigation history. (natlawreview.com) (congress.gov) There is also a congressional angle. The Congressional Research Service noted in 2025 that regulation of laboratory-developed tests has been a subject of ongoing debate in Congress, and past legislative efforts have tried to create a more explicit framework for diagnostics oversight. That means the fiscal year 2027 budget should be read not just as an agency planning document, but as part of a longer campaign to persuade lawmakers to settle the question directly. (congress.gov) For laboratories planning cytology-based molecular menus, the immediate takeaway is not that a new rule has arrived. The takeaway is that the Food and Drug Administration is still using formal budget materials to point toward a future in which diagnostic oversight could be revisited through legislation, targeted enforcement, or both. (fda.gov) (natlawreview.com) The safest reading is that the legal status quo today is more favorable to laboratories than it was in mid-2024, because the 2024 final rule was vacated and the regulation text was formally reverted in September 2025. But the policy fight is not over, and the fiscal year 2027 budget is a reminder that the Food and Drug Administration is still signaling interest in stronger tools and clearer authority. (fda.gov) ([congress.gov](https://www.congress.gov/crs